# US 2024/0199638 A1 · Glutarimides for medical treatment

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0199638 A1
- Document ID: US20240199638A1
- Status: Published application
- Kind: A1
- Application number: 18/385,277
- Filed: 2023-10-30
- Published: 2024-06-20
- Earliest claimed: 2017-09-04
- Assignees: C4 Therapeutics, Inc.
- Applicants: C4 Therapeutics, Inc.
- Inventors: Roger Norcross; Annick Goergler; Philipp Schmid; Fabian Dey; Eric Andre Kusznir
- Web page: https://patentgrep.com/patent/US20240199638A1

## CPC

- C07D 495/14: Ortho-condensed systems
- A61K 31/4412: having oxo groups directly attached to the heterocyclic ring
- A61K 31/4709: Non-condensed quinolines and containing further heterocyclic rings
- A61K 31/498: Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
- A61K 47/55: the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug
- C07D 211/88: attached in positions 2 and 6, e.g. glutarimide
- C07D 401/12: linked by a chain containing hetero atoms as chain links
- C07D 405/12: linked by a chain containing hetero atoms as chain links
- C07D 409/12: linked by a chain containing hetero atoms as chain links
- C07D 471/04: Ortho-condensed systems
- C07D 487/04: Ortho-condensed systems
- C07D 519/00: Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The present invention provides selected glutarimides which bind to the ubiquitously expressed E3 ligase protein cereblon (CRBN) and alter the substrate specificity of the CRBN E3 ubiquitin ligase complex, resulting in breakdown of intrinsic downstream proteins. The disclosed compounds are useful for the treatment of cancer.

## Claims

### Claim 1

A method for the treatment of cancer comprising administering an effective amount of a compound of formula I, or a pharmaceutically acceptable salt thereof to a human patient,
wherein
R1 is selected from the group consisting of
i) aryl, optionally substituted by one R3 substituent,
ii) heterocycloalkyl, optionally substituted by one R4 substituent,
iii) cycloalkyl, optionally substituted by one R5 substituent, and
iv) heteroaryl, optionally substituted by one R6 substituent,
R2 is H, C1-6alkyl or —NC(═O)—C1-4alkyl,
R3 is H or C1-6alkyl,
R4 is H or C1-6alkyl,
R5 is H or C1-6alkyl,
R6 is H, C1-6alkyl, —C(═O)O—C1-6alkyl or oxo,
n is 0 or 1.

### Claim 2 (depends on 1)

The method of claim 1, wherein
R1 is selected from the group consisting of
i) aryl, optionally substituted by one R3 substituent,
ii) heterocycloalkyl, optionally substituted by one R4 substituent,
iii) cycloalkyl, optionally substituted by one R5 substituent, and
iv) heteroaryl, optionally substituted by one R6 substituent,
R2 is H or C1-6alkyl,
R3 is H or C1-6alkyl,
R4 is H or C1-6alkyl,
R5 is H or C1-6alkyl,
R6 is H or C1-6alkyl,
n is 0 or 1.

### Claim 3 (depends on 1)

The method of claim 1, wherein R2 is hydrogen.

### Claim 4 (depends on 1)

The method of claim 1, wherein R2 is methyl.

### Claim 5 (depends on 1)

The method of claim 1, wherein n is 0.

### Claim 6 (depends on 1)

The method of claim 1, wherein n is 1.

### Claim 7 (depends on 1)

The method of claim 1, wherein R1 is selected from 1,2,3,4-tetrahydronaphthalenyl, 1,2,3,4-tetrahydroquinolinyl, 1H-indolyl, 2,3-dihydro-1H-pyrrolo[2,3-b]pyridinyl, and 6,7-dihydro-5H-cyclopenta[b]pyridinyl.

### Claim 8 (depends on 1)

The method of claim 1, wherein R1 is selected from benzofuranyl, benzothiophenyl, chromanyl, indanyl, indolinyl, isoindolinyl, and tetralinyl.

### Claim 9 (depends on 1)

The method of claim 1, wherein the compound is of the formula:
or a pharmaceutically acceptable salt thereof.

### Claim 10 (depends on 1)

The method of claim 1, wherein the compound is of the formula:
or a pharmaceutically acceptable salt thereof.

### Claim 11 (depends on 1)

The method of claim 1, wherein the compound is of the formula:
or a pharmaceutically acceptable salt thereof.

### Claim 12 (depends on 1)

The method of claim 1, wherein the compound is of the formula:
or a pharmaceutically acceptable salt thereof.

### Claim 13 (depends on 1)

The method of claim 1, wherein the compound is of the formula:
or a pharmaceutically acceptable salt thereof.

### Claim 14 (depends on 1)

The method of claim 1, wherein the compound is of the formula:
or a pharmaceutically acceptable salt thereof.

### Claim 15 (depends on 1)

The method of claim 1, wherein the compound is of the formula:
or a pharmaceutically acceptable salt thereof.
